Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to 0.41%.

  • Crinetics Pharmaceuticals' Return on Capital Employed fell 600.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.35% for FY2024, which is 1500.0% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.41% for Q3 2025, which was down 600.0% from 0.34% recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Return on Capital Employed ranged from a high of 0.28% in Q1 2025 and a low of 0.71% during Q2 2023
  • In the last 5 years, Crinetics Pharmaceuticals' Return on Capital Employed had a median value of 0.39% in 2021 and averaged 0.41%.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Return on Capital Employed plummeted by -3200bps in 2023, and later skyrocketed by 4000bps in 2024.
  • Crinetics Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.39% in 2021, then dropped by -26bps to 0.49% in 2022, then increased by 24bps to 0.37% in 2023, then grew by 20bps to 0.3% in 2024, then plummeted by -36bps to 0.41% in 2025.
  • Its Return on Capital Employed was 0.41% in Q3 2025, compared to 0.34% in Q2 2025 and 0.28% in Q1 2025.